苯扎贝特与氯贝丁酯治疗ⅡB型和Ⅳ型高脂蛋白血症的比较
[A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
作者信息
Bolzano K, Krempler F, Schellenberg B, Schlierf G
出版信息
Acta Med Austriaca. 1979;6(3):90-4.
In 36 patients with primary hyperlipoproteinemia of type II B or IV the effect of bezafibrate, a new derivate of clofibrate, has been compared with the effect of clofibrate. In an open cross-over-study the effect of 1.5 g clofibrate p.d. has been compared with that of 450 mg bezafibrate p.d. for several months. The effect of bezafibrate on plasma triglyceride concentration and plasma cholesterol concentration was more pronounced than that of clofibrate. This difference was statistically significantly only in the concentration of plasma triglycerides of type IV patients. It is obvious that the difference between bezafibrate and clofibrate would have been more pronounced if the dose of bezafibrate had been in the optimal range. Serious side-effects caused by bezafibrate could not be observed.
在36例II B型或IV型原发性高脂蛋白血症患者中，比较了氯贝丁酯的新衍生物苯扎贝特与氯贝丁酯的疗效。在一项开放性交叉研究中，将每日1.5 g氯贝丁酯的疗效与每日450 mg苯扎贝特的疗效进行了数月的比较。苯扎贝特对血浆甘油三酯浓度和血浆胆固醇浓度的影响比氯贝丁酯更显著。这种差异仅在IV型患者的血浆甘油三酯浓度方面具有统计学意义。显然，如果苯扎贝特的剂量处于最佳范围，其与氯贝丁酯之间的差异会更加显著。未观察到苯扎贝特引起的严重副作用。
Zotero 插件